Bristol-Myers Squibb Company (BMY)
NYSE • Healthcare
May 20, 2026 at 16:00 UTC
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is a biopharmaceutical enterprise that discovers, develops, and commercializes medicines in oncology, immunology, cardiovascular disease, and other therapeutic areas. Research programs span biologics and small molecules guided by translational science, clinical development, and collaborations with academic groups and biotechnology partners. Manufacturing and quality systems support global supply for hospitals and pharmacies, while medical affairs and patient services help clinicians use therapies appropriately. The company engages regulators and health systems across North America, Europe, and key international markets, aligning access strategies with local standards of care. Within the healthcare ecosystem, Bristol-Myers Squibb contributes targeted treatments and pursues pipelines intended to address complex, chronic conditions.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Bristol-Myers Squibb Company's Technical Indicators Summary
Bristol Myers displays a modestly bullish technical posture with the stock trading above several short- and medium-term moving averages and well above the longer-term EMA, while momentum measures show mild upside and the RSI sits near neutral. Trend strength is weak per the low ADX, so the advance lacks strong conviction, and volatility is subdued by a modest ATR, which points to orderly movement. On-balance volume signals suggest accumulation even though VWAP sits near the current price, leaving intraday bias mixed. Technical takeaway: bullish bias supported by price above key averages but without strong trend conviction.
| Indicator | Value |
|---|---|
RSI (14) | 53.81 |
Stochastic %K (14, 3, 3) | 50.66 |
CCI (20) | 77.05 |
WPR (14) | -37.39 |
Momentum (10) | 1.75 |
MFI | 42.24 |
MACD Level (12, 26) | -0.32 |
Bollinger Bands | $55.11 - $59.87 |
ATR (14) | $1.28 (2.20%) |
ADX (14) | 12.93 |
OBV | -26,859,312 |
VWAP | $58.67 |
Classic Pivot Point | $58.01 |
Fibonacci Pivot Point | $58.01 |
Simple Moving Averages | $56.87 - $58.40(5 indicators) |
Exponential Moving Averages | $53.50 - $57.97(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
By the bell, BMY remained somewhat elevated, with the 0.35% gap versus yesterday leaving it around 58.52. Into the bell, a flat sector move (-0.12%) kept the backdrop muted. BMY is buoyed by a Bristol-Myers-Anthropic AI deal aimed at faster drug discovery, amid a muted sector.
Price Change
from $58.52 close
$0
Trading Volume
Below avg (9.5M)
5.2M
vs S&P 500 Today
Underperforming Market
-0.85%
52-Week Position
Upper range
78.5%
Updated: May 20, 2026 at 20:03 UTC
Quote Summary
BMY Headlines
Fresh Valuation Checks Across Key Stocks
April 4, 2026
Colgate-Palmolive faces key board, dividend moves
March 26, 2026
AI, Capital Moves Shape Key Stock Narratives
March 15, 2026
Markets Swoon as Bitcoin, Tech and Crypto Firms Slide
February 5, 2026